<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CAT</journal-id>
<journal-id journal-id-type="hwp">spcat</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Appl Thromb Hemost</journal-id>
<journal-title>Clinical and Applied Thrombosis/Hemostasis</journal-title>
<issn pub-type="ppub">1076-0296</issn>
<issn pub-type="epub">1938-2723</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1076029613491346</article-id>
<article-id pub-id-type="publisher-id">10.1177_1076029613491346</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Erratum</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Erratum</article-title>
</title-group>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>3</issue>
<fpage>344</fpage>
<lpage>349</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<related-article issue="2" page="208" related-article-type="corrected-article" vol="19" xlink:href="10.1177/1076029612474840s"/>
</article-meta>
</front>
<body>
<p>In CATH, Volume 19, Issue number 2, March/April 2013, Chapter 19 titled “Heparin-Induced Thrombocytopenia” was inadvertently omitted.</p>
<p>The omitted chapter is published in the current issue, CATH 19:3 May/June. For the complete updated CATH 19:2 March/April issue, please log on to http://cat.sagepub.com.</p>
<p>SAGE deeply regrets the error.</p>
<sec id="section1-1076029613491346">
<title>Heparin-Induced Thrombocytopenia</title>
<sec id="section4-1076029613491346">
<title>General Considerations</title>
<p>Heparin-induced thrombocytopenia (HIT) is an important adverse effect of heparin. HIT is a life-threatening prothrombotic, immune-mediated coagulopathy caused by antibodies that bind to the complex of platelet factor 4 (PF4) and heparin.<sup><xref ref-type="bibr" rid="bibr1-1076029613491346">1</xref></sup> HIT occurs most frequently after cardiac or orthopedic surgery or in medical patients<sup><xref ref-type="bibr" rid="bibr2-1076029613491346">2</xref><xref ref-type="bibr" rid="bibr3-1076029613491346"/>
<xref ref-type="bibr" rid="bibr4-1076029613491346"/>
<xref ref-type="bibr" rid="bibr5-1076029613491346"/>
<xref ref-type="bibr" rid="bibr6-1076029613491346"/>
<xref ref-type="bibr" rid="bibr7-1076029613491346"/>
<xref ref-type="bibr" rid="bibr8-1076029613491346"/>
<xref ref-type="bibr" rid="bibr9-1076029613491346"/>–<xref ref-type="bibr" rid="bibr10-1076029613491346">10</xref></sup> but can also be found in other patient populations and clinical settings.<sup><xref ref-type="bibr" rid="bibr11-1076029613491346">11</xref><xref ref-type="bibr" rid="bibr12-1076029613491346"/>
<xref ref-type="bibr" rid="bibr13-1076029613491346"/>
<xref ref-type="bibr" rid="bibr14-1076029613491346"/>–<xref ref-type="bibr" rid="bibr15-1076029613491346">15</xref></sup> Progression to overt thrombosis, which can occur anywhere throughout the venous and arterial circulation, is the most serious complication of HIT, as it often leads to amputation or death.<sup><xref ref-type="bibr" rid="bibr16-1076029613491346">16</xref><xref ref-type="bibr" rid="bibr17-1076029613491346"/>
<xref ref-type="bibr" rid="bibr18-1076029613491346"/>–<xref ref-type="bibr" rid="bibr19-1076029613491346">19</xref></sup> Spontaneous bleeding and petechiae are rare.</p>
<p>HIT (also known as HIT type II) needs to be distinguished from other more common and benign causes of thrombocytopenia, such as HIT type I and pseudothrombocytopenia. HIT type I is a transient but self-limited fall in platelet count that occurs in up to 30% of the treated patients. It results from a nonimmunological mechanism in the first 24 hours of receiving heparin and resolves within 24 to 48 hours.<sup><xref ref-type="bibr" rid="bibr20-1076029613491346">20</xref></sup></p>
<p>The frequency of HIT is influenced by several factors. The risk of developing HIT is higher when exposed to unfractionated heparin (UFH; bovine more than porcine<sup><xref ref-type="bibr" rid="bibr21-1076029613491346">21</xref></sup>) than low-molecular-weight heparin (LMWH)<sup><xref ref-type="bibr" rid="bibr7-1076029613491346">7</xref>,<xref ref-type="bibr" rid="bibr22-1076029613491346">22</xref><xref ref-type="bibr" rid="bibr23-1076029613491346"/>
<xref ref-type="bibr" rid="bibr24-1076029613491346"/>
<xref ref-type="bibr" rid="bibr25-1076029613491346"/>
<xref ref-type="bibr" rid="bibr26-1076029613491346"/>–<xref ref-type="bibr" rid="bibr27-1076029613491346">27</xref></sup> and is more duration dependent than dose dependent.<sup><xref ref-type="bibr" rid="bibr8-1076029613491346">8</xref>,<xref ref-type="bibr" rid="bibr28-1076029613491346">28</xref>,<xref ref-type="bibr" rid="bibr29-1076029613491346">29</xref></sup> However, HIT can occur with a higher frequency in LMWH-treated patients who were previously exposed to UFH.<sup><xref ref-type="bibr" rid="bibr29-1076029613491346">29</xref></sup> HIT due to LMWH is as severe as UFH-induced HIT.<sup><xref ref-type="bibr" rid="bibr22-1076029613491346">22</xref></sup> HIT can also occur with prophylactic doses of heparin<sup><xref ref-type="bibr" rid="bibr28-1076029613491346">28</xref></sup> and heparin from exogenous sources (eg, heparin flushes and heparin-coated catheters).<sup><xref ref-type="bibr" rid="bibr30-1076029613491346">30</xref></sup> Preventive measures include the use of LMWH, fondaparinux, and nonheparin anticoagulants rather than UFH for postsurgical prophylaxis, use of porcine rather than bovine UFH, and avoiding unnecessary and prolonged exposure to UFH.</p>
<p>The diagnosis of HIT is based on the clinical findings and platelet count. In patients being treated or having been recently treated with heparin, HIT should be suspected on the basis of a 30% decrease in platelet count from baseline in the absence of other reasons for thrombocytopenia.<sup><xref ref-type="bibr" rid="bibr1-1076029613491346">1</xref>,<xref ref-type="bibr" rid="bibr31-1076029613491346">31</xref>,<xref ref-type="bibr" rid="bibr32-1076029613491346">32</xref></sup> The diagnosis can be made if the platelet count reduction is 50% of the baseline, assuming no other reasons for thrombocytopenia.<sup><xref ref-type="bibr" rid="bibr1-1076029613491346">1</xref>,<xref ref-type="bibr" rid="bibr31-1076029613491346">31</xref>,<xref ref-type="bibr" rid="bibr32-1076029613491346">32</xref></sup> An abrupt decrease in platelet count in the absence of other causes, which does not result in thrombocytopenia (eg, platelet count may fall from 350 to 175 × 10<sup>9</sup>/L) and unexplained thrombosis are also characteristics of HIT.<sup><xref ref-type="bibr" rid="bibr1-1076029613491346">1</xref>,<xref ref-type="bibr" rid="bibr31-1076029613491346">31</xref>,<xref ref-type="bibr" rid="bibr32-1076029613491346">32</xref></sup> Symptoms typically appear 4 to 14 days after exposure to UFH<sup><xref ref-type="bibr" rid="bibr33-1076029613491346">33</xref>,<xref ref-type="bibr" rid="bibr34-1076029613491346">34</xref></sup> or 8 to 14 days after exposure to LMWH.<sup><xref ref-type="bibr" rid="bibr22-1076029613491346">22</xref></sup> Patients who received heparin within the prior 100 days can have an immediate rapid onset HIT when restarting UFH or LMWH.<sup><xref ref-type="bibr" rid="bibr33-1076029613491346">33</xref>,<xref ref-type="bibr" rid="bibr34-1076029613491346">34</xref></sup> Delayed onset HIT has been observed with symptoms appearing several days after discontinuation of UFH.<sup><xref ref-type="bibr" rid="bibr1-1076029613491346">1</xref>,<xref ref-type="bibr" rid="bibr35-1076029613491346">35</xref></sup></p>
<p>The diagnosis of HIT is difficult in patients who underwent surgery, as postoperative thrombocytopenia is frequently present after a surgical procedure. It is particularly difficult after cardiac surgery, because the platelet count always falls following cardiac surgery using cardiopulmonary bypass. In these patients, HIT should be suspected if the platelet count recovery in the immediate postoperative period is interrupted by a sudden and marked platelet count decrease in 5 to 10 days postoperation (a biphasic platelet count pattern).<sup><xref ref-type="bibr" rid="bibr36-1076029613491346">36</xref><xref ref-type="bibr" rid="bibr37-1076029613491346"/>–<xref ref-type="bibr" rid="bibr38-1076029613491346">38</xref></sup> However, HIT cannot be definitely excluded in these patients if there is a monophasic pattern of persistent postoperative thrombocytopenia.<sup><xref ref-type="bibr" rid="bibr36-1076029613491346">36</xref><xref ref-type="bibr" rid="bibr37-1076029613491346"/>–<xref ref-type="bibr" rid="bibr38-1076029613491346">38</xref></sup></p>
<p>Another clinical presentation of HIT that can be challenging is where a patient has only mild thrombocytopenia receiving heparin or LMWH treatment. Such patients need to be individually assessed for their risk of having HIT considering past exposure to heparin, competing causes for thrombocytopenia, and new thrombosis. The level of risk will determine whether or not to continue heparin or LMWH treatment, while laboratory testing is sent to confirm the diagnosis.<sup><xref ref-type="bibr" rid="bibr39-1076029613491346">39</xref></sup></p>
<p>Clinical scoring systems are available and continue to be developed to assist in the diagnosis of HIT.<sup><xref ref-type="bibr" rid="bibr36-1076029613491346">36</xref>,<xref ref-type="bibr" rid="bibr39-1076029613491346">39</xref><xref ref-type="bibr" rid="bibr40-1076029613491346"/>–<xref ref-type="bibr" rid="bibr41-1076029613491346">41</xref></sup></p>
<p>A clinical diagnosis of HIT should be confirmed by a laboratory assay that detects heparin-dependent antibodies. Pathologic HIT immune complexes are composed of the PF4-heparin complex bound to an immunoglobulin (Ig) G.<sup><xref ref-type="bibr" rid="bibr42-1076029613491346">42</xref><xref ref-type="bibr" rid="bibr43-1076029613491346"/>
<xref ref-type="bibr" rid="bibr44-1076029613491346"/>
<xref ref-type="bibr" rid="bibr45-1076029613491346"/>–<xref ref-type="bibr" rid="bibr46-1076029613491346">46</xref></sup> These complexes bind to platelet FcγIIa receptors (CD 32) inducing platelet activation, aggregation, and generation of platelet microparticles.<sup><xref ref-type="bibr" rid="bibr47-1076029613491346">47</xref>,<xref ref-type="bibr" rid="bibr48-1076029613491346">48</xref></sup> IgA and IgM have also been identified in patients with HIT.<sup><xref ref-type="bibr" rid="bibr49-1076029613491346">49</xref></sup> The HIT antibodies provoke leukocyte and endothelial cell activation that augment both the hypercoagulable and the inflammatory states.<sup><xref ref-type="bibr" rid="bibr44-1076029613491346">44</xref>,<xref ref-type="bibr" rid="bibr50-1076029613491346">50</xref><xref ref-type="bibr" rid="bibr51-1076029613491346"/>
<xref ref-type="bibr" rid="bibr52-1076029613491346"/>
<xref ref-type="bibr" rid="bibr53-1076029613491346"/>–<xref ref-type="bibr" rid="bibr54-1076029613491346">54</xref></sup> This combined cellular activation leads to a burst of thrombin generation.<sup><xref ref-type="bibr" rid="bibr55-1076029613491346">55</xref></sup> In all patients at risk of thrombosis, those with HIT are at highest risk (&gt;30%).<sup><xref ref-type="bibr" rid="bibr31-1076029613491346">31</xref></sup> Nondrug factors, such as type of surgery, severity of trauma, severity of thrombocytopenia (particularly at baseline), renal impairment, low cardiac output, and timing of first anticoagulant dose, also influence the risk of developing HIT and related clinical outcomes.<sup><xref ref-type="bibr" rid="bibr56-1076029613491346">56</xref><xref ref-type="bibr" rid="bibr57-1076029613491346"/>
<xref ref-type="bibr" rid="bibr58-1076029613491346"/>–<xref ref-type="bibr" rid="bibr59-1076029613491346">59</xref></sup> The association of HIT antibodies, in the absence of thrombocytopenia and thrombosis, with future cardiovascular and other thrombotic events has been reported and remains under investigation.<sup><xref ref-type="bibr" rid="bibr60-1076029613491346">60</xref></sup></p>
<p>There are 2 types of laboratory assays that detect heparin-dependent antibodies. These are platelet function tests (serotonin release and platelet aggregation assays) and immunoassays that detect antibodies to the PF4-heparin complex.<sup><xref ref-type="bibr" rid="bibr61-1076029613491346">61</xref><xref ref-type="bibr" rid="bibr62-1076029613491346"/>
<xref ref-type="bibr" rid="bibr63-1076029613491346"/>–<xref ref-type="bibr" rid="bibr64-1076029613491346">64</xref></sup> Each test has particular performance characteristics and provides unique information, so that appropriate use and knowledgeable interpretation of the test results are important.<sup><xref ref-type="bibr" rid="bibr64-1076029613491346">64</xref><xref ref-type="bibr" rid="bibr65-1076029613491346"/>
<xref ref-type="bibr" rid="bibr66-1076029613491346"/>–<xref ref-type="bibr" rid="bibr67-1076029613491346">67</xref></sup> Platelet function assays that use washed platelets have a better sensitivity than plasma-based assays, but false negative results can still be obtained. Immunoassays have a high rate of positive results that are not always associated with clinical HIT in the patient.<sup><xref ref-type="bibr" rid="bibr65-1076029613491346">65</xref>,<xref ref-type="bibr" rid="bibr68-1076029613491346">68</xref><xref ref-type="bibr" rid="bibr69-1076029613491346"/>–<xref ref-type="bibr" rid="bibr70-1076029613491346">70</xref></sup> For immunoassays, the option to report the titer results rather than a simple positive or negative result and to utilize the high heparin concentration confirmatory step are gaining favor, as these provide a closer correlation with the risk of thrombosis and mortality in patients with HIT.<sup><xref ref-type="bibr" rid="bibr26-1076029613491346">26</xref>,<xref ref-type="bibr" rid="bibr71-1076029613491346">71</xref><xref ref-type="bibr" rid="bibr72-1076029613491346"/>
<xref ref-type="bibr" rid="bibr73-1076029613491346"/>
<xref ref-type="bibr" rid="bibr74-1076029613491346"/>–<xref ref-type="bibr" rid="bibr75-1076029613491346">75</xref></sup> Exclusive reliance on laboratory tests for the diagnosis of HIT can lead to erroneous diagnostic conclusions.</p>
<p>Clinical trials and clinical experience have shown the direct thrombin inhibitors (DTIs) argatroban<sup><xref ref-type="bibr" rid="bibr76-1076029613491346">76</xref><xref ref-type="bibr" rid="bibr77-1076029613491346"/>
<xref ref-type="bibr" rid="bibr78-1076029613491346"/>
<xref ref-type="bibr" rid="bibr79-1076029613491346"/>
<xref ref-type="bibr" rid="bibr80-1076029613491346"/>
<xref ref-type="bibr" rid="bibr81-1076029613491346"/>–<xref ref-type="bibr" rid="bibr82-1076029613491346">82</xref></sup> and lepirudin<sup><xref ref-type="bibr" rid="bibr83-1076029613491346">83</xref>,<xref ref-type="bibr" rid="bibr84-1076029613491346">84</xref></sup> to be safe and effective in reducing the risk of thrombosis and associated morbidity or mortality in patients with HIT. These drugs do not cross-react with HIT antibodies. Development of antibodies to lepirudin has been observed in approximately 50% of the patients after 10 days of treatment, including severe anaphylactic reactions with fatal outcomes in cases of reexposure to lepirudin.<sup><xref ref-type="bibr" rid="bibr85-1076029613491346">85</xref>,<xref ref-type="bibr" rid="bibr86-1076029613491346">86</xref></sup> Dose adjustments for argatroban in specific populations<sup><xref ref-type="bibr" rid="bibr79-1076029613491346">79</xref>,<xref ref-type="bibr" rid="bibr87-1076029613491346">87</xref>,<xref ref-type="bibr" rid="bibr88-1076029613491346">88</xref></sup> and for lepirudin in general<sup><xref ref-type="bibr" rid="bibr89-1076029613491346">89</xref><xref ref-type="bibr" rid="bibr90-1076029613491346"/>–<xref ref-type="bibr" rid="bibr91-1076029613491346">91</xref></sup> have been recently recommended. The DTI desirudin, which has the advantage of subcutaneous dosing, has been successfully used in a limited number of patients with HIT.<sup><xref ref-type="bibr" rid="bibr92-1076029613491346">92</xref>,<xref ref-type="bibr" rid="bibr93-1076029613491346">93</xref></sup> The DTI bivalirudin, which has a short half-life and enzymatic degradation, has been used for anticoagulation in patients with HIT during cardiac surgery.<sup><xref ref-type="bibr" rid="bibr94-1076029613491346">94</xref><xref ref-type="bibr" rid="bibr95-1076029613491346"/>–<xref ref-type="bibr" rid="bibr96-1076029613491346">96</xref></sup> The DTIs have also been used successfully in patients with HIT requiring invasive cardiac procedures.<sup><xref ref-type="bibr" rid="bibr97-1076029613491346">97</xref>,<xref ref-type="bibr" rid="bibr98-1076029613491346">98</xref></sup> The DTIs should be treated as individual drugs, as each has its own pharmacologic characteristics.</p>
<p>The heparinoid danaparoid has been successfully used to treat patients with HIT,<sup><xref ref-type="bibr" rid="bibr99-1076029613491346">99</xref><xref ref-type="bibr" rid="bibr100-1076029613491346"/>–<xref ref-type="bibr" rid="bibr101-1076029613491346">101</xref></sup> but there are reports that danaparoid cross-reacts with some HIT antibodies leading to treatment failures.<sup><xref ref-type="bibr" rid="bibr101-1076029613491346">101</xref><xref ref-type="bibr" rid="bibr102-1076029613491346"/>
<xref ref-type="bibr" rid="bibr103-1076029613491346"/>
<xref ref-type="bibr" rid="bibr104-1076029613491346"/>–<xref ref-type="bibr" rid="bibr105-1076029613491346">105</xref></sup> The synthetic heparin pentasaccharide, fondaparinux, has been shown to be useful for the management of patients with HIT through several small published case series and is gaining favor.<sup><xref ref-type="bibr" rid="bibr106-1076029613491346">106</xref><xref ref-type="bibr" rid="bibr107-1076029613491346"/>
<xref ref-type="bibr" rid="bibr108-1076029613491346"/>–<xref ref-type="bibr" rid="bibr109-1076029613491346">109</xref></sup></p>
<p>The LMWHs can cross-react with most HIT antibodies and are contraindicated for use in patients with HIT.<sup><xref ref-type="bibr" rid="bibr27-1076029613491346">27</xref>,<xref ref-type="bibr" rid="bibr110-1076029613491346">110</xref>,<xref ref-type="bibr" rid="bibr111-1076029613491346">111</xref></sup></p>
<p>Vitamin K antagonists (VKAs) are recommended for long-term treatment of HIT-associated thrombosis.<sup><xref ref-type="bibr" rid="bibr31-1076029613491346">31</xref></sup> The VKAs are not recommended for use in the acute phase of HIT due to their potential to intensify the prothrombotic state from a transient protein C deficiency.<sup><xref ref-type="bibr" rid="bibr112-1076029613491346">112</xref>,<xref ref-type="bibr" rid="bibr113-1076029613491346">113</xref></sup> The VKAs should be initiated when platelet counts have normalized to a steady state, then brought on underbridged with a DTI.<sup><xref ref-type="bibr" rid="bibr114-1076029613491346">114</xref><xref ref-type="bibr" rid="bibr115-1076029613491346"/>–<xref ref-type="bibr" rid="bibr116-1076029613491346">116</xref></sup></p>
<p>There is emerging evidence that the newly developed small molecule anticoagulants including apixaban, dabigatran, edoxaban, otamixaban, and rivaroxaban may become new immediate and long-term treatment options for thrombosis in patients with HIT.<sup><xref ref-type="bibr" rid="bibr109-1076029613491346">109</xref></sup></p>
</sec>
<sec id="section2-1076029613491346">
<title>Recommendations</title>
<p>Early diagnosis and treatment are important to improve clinical outcomes. Diagnosis of HIT is based on a comprehensive interpretation of clinical and laboratory information.</p>
<p>For the first 14 days of treatment, platelet counts should be performed every 2 to 3 days in patients treated with LMWH and daily if treated with UFH and if the patient’s risk of developing HIT is high (level of evidence: moderate). For medical and obstetric patients treated with LMWH exclusively and no prior exposure to UFH, it is no longer considered necessary to monitor the platelet count. Patients with comorbidities are at higher risk of poorer clinical outcomes. All clinical settings including the emergency department need to be aware of a patient’s history of HIT and prior UFH or LMWH exposure.</p>
<p>Several clinical scoring systems are available, which can help diagnose HIT. Laboratory testing should be performed when there is a strong suspicion of HIT (level of evidence: moderate). Laboratory tests are used to confirm a diagnosis of HIT, but negative results do not exclude the diagnosis. It is useful to perform a combination of tests and to repeat testing over a period of several days. Initial therapeutic decisions should not be dependent upon a positive laboratory test but should be based upon clinical findings, particularly thrombocytopenia and/or new thromboembolic events.</p>
<p>UFH and LMWH should be stopped when the diagnosis of HIT is strongly suspected or confirmed (level of evidence: high). It is not sufficient to merely remove the heparin. Due to the strong hypercoagulable state and high risk of thrombosis associated with HIT, it is recommended that all patients with HIT be treated with a nonheparin anticoagulant such as argatroban, lepirudin, or danaparoid (level of evidence: moderate). Differences between these drugs need to be considered when making a clinical treatment decision (eg, patient’s renal or liver clearance, drug pharmacokinetics, patient’s risk of bleeding, prior exposure of patient to lepirudin, physician’s experience with the drug, drug availability, acute anticoagulant need, long-term treatment, cross-reactivity of drug to HIT antibodies, etc). With danaparoid treatment, if daily platelet counts do not show signs of recovery within 3 days, it is mandatory to check for immune cross-reactivity of patient’s antibodies to danaparoid using a functional platelet assay and discontinue treatment if positive. Fondaparinux may be considered as a second-line agent in the management of patients with suspected HIT (level of evidence: low). The LMWHs are contraindicated in patients with HIT (level of evidence: moderate).</p>
<p>For long-term anticoagulation, a VKA can be used. To avoid warfarin-induced limb gangrene or skin necrosis in patients with HIT, the VKA should only be administered after rise in platelet counts, with substantial recovery to &gt;100 × 10<sup>9</sup>/L or to pre-HIT values (level of evidence: low). Starting doses need to be low (5 mg warfarin and 6 mg phenprocoumon) and given with overlapping administration of argatroban, lepirudin, or danaparoid for at least 5 days.</p>
<p>For patients with HIT undergoing coronary artery interventional procedures, bivalirudin or argatroban anticoagulation is recommended (level of evidence: moderate). For special populations of patients with HIT requiring anticoagulation such as pregnant or pediatric patients or patients undergoing cardiac surgery or hemodialysis, specific drug and dose issues need to be considered. For postoperative cardiac surgery patients, LMWH, and not, UFH should be used to decrease the risk of developing HIT, and if HIT is suspected, a nonheparin anticoagulant should be used.</p>
</sec>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="bibr1-1076029613491346">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arepally</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cines</surname>
<given-names>DB</given-names>
</name>
</person-group>. <article-title>Heparin-induced thrombocytopenia and thrombosis</article-title>. <source>Clin Rev Allergy Immunol</source>. <year>1998</year>;<volume>16</volume>(<issue>3</issue>):<fpage>237</fpage>–<lpage>247</lpage>.</citation>
</ref>
<ref id="bibr2-1076029613491346">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Steen</surname>
<given-names>LH</given-names>
</name>
<etal/>
</person-group>. <article-title>Patency of coronary artery bypass grafts in patients with heparin-induced thrombocytopenia</article-title>. <source>Am J Cardiol</source>. <year>2002</year>;<volume>89</volume>(<issue>8</issue>):<fpage>979</fpage>–<lpage>981</lpage>.</citation>
</ref>
<ref id="bibr3-1076029613491346">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verma</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Levine</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shalansky</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Kelton</surname>
<given-names>JG</given-names>
</name>
</person-group>. <article-title>Frequency of heparin-induced thrombocytopenia in critical care patients</article-title>. <source>Pharmacotherapy</source>. <year>2003</year>;<volume>23</volume>(<issue>6</issue>):<fpage>745</fpage>–<lpage>753</lpage>.</citation>
</ref>
<ref id="bibr4-1076029613491346">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warkentin</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Sheppard</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Horsewood</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Simpson</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Kelton</surname>
<given-names>JG</given-names>
</name>
</person-group>. <article-title>Impact of the patient population on the risk for heparin-induced thrombocytopenia</article-title>. <source>Blood</source>. <year>2000</year>;<volume>96</volume>(<issue>5</issue>):<fpage>1703</fpage>–<lpage>1708</lpage>.</citation>
</ref>
<ref id="bibr5-1076029613491346">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warkentin</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Hirsh</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kelton</surname>
<given-names>JG</given-names>
</name>
</person-group>. <article-title>An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients</article-title>. <source>Arch Intern Med</source>. <year>2003</year>;<volume>163</volume>(<issue>20</issue>):<fpage>2518</fpage>–<lpage>2524</lpage>.</citation>
</ref>
<ref id="bibr6-1076029613491346">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Girolami</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Prandoni</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Stefani</surname>
<given-names>PM</given-names>
</name>
<etal/>
</person-group>. <article-title>The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study</article-title>. <source>Blood</source>. <year>2003</year>;<volume>101</volume>(<issue>8</issue>):<fpage>2955</fpage>–<lpage>2959</lpage>.</citation>
</ref>
<ref id="bibr7-1076029613491346">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wells</surname>
<given-names>PS</given-names>
</name>
</person-group>. <article-title>Risk for heparin-induced thrombocytopenia with unfractionated heparin and low-molecular-weight heparin thromboprophylaxis: a meta-analysis</article-title>. <source>Blood</source>. <year>2005</year>;<volume>106</volume>(<issue>8</issue>):<fpage>2710</fpage>.</citation>
</ref>
<ref id="bibr8-1076029613491346">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smythe</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Koerber</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Mattson</surname>
<given-names>JC</given-names>
</name>
</person-group>. <article-title>The incidence of recognized heparin-induced thrombocytopenia in a large tertiary care, teaching hospital</article-title>. <source>Chest</source>. <year>2007</year>;<volume>131</volume>(<issue>6</issue>):<fpage>1644</fpage>–<lpage>1649</lpage>.</citation>
</ref>
<ref id="bibr9-1076029613491346">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crespo</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Olivera</surname>
<given-names>GBF</given-names>
</name>
<name>
<surname>Honeycutt</surname>
<given-names>EF</given-names>
</name>
<etal/>
</person-group>. <article-title>Evaluation and management of thrombocytopenia and suspected heparin induced thrombocytopenia in hospitalized patients. The complications after thrombocytopenia caused by heparin (CATCH) registry</article-title>. <source>Am Heart J</source>. <year>2009</year>;<volume>157</volume>(<issue>4</issue>):<fpage>651</fpage>–<lpage>657</lpage>.</citation>
</ref>
<ref id="bibr10-1076029613491346">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walls</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Curtis</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Silver</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Boley</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Schmaltz</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Nawarawong</surname>
<given-names>W</given-names>
</name>
</person-group>. <article-title>Heparin-induced thrombocytopenia in open heart surgical patients: sequelae of late recognition</article-title>. <source>Ann Thorac Surg</source>. <year>1992</year>;<volume>53</volume>(<issue>5</issue>):<fpage>787</fpage>–<lpage>791</lpage>.</citation>
</ref>
<ref id="bibr11-1076029613491346">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsuo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tomaru</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kario</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hirokawa</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Incidence of heparin-PF4 complex antibody formation and heparin-induced thrombocytopenia in acute coronary syndrome</article-title>. <source>Thromb Res</source>. <year>2005</year>;<volume>115</volume>(<issue>6</issue>):<fpage>475</fpage>–<lpage>481</lpage>.</citation>
</ref>
<ref id="bibr12-1076029613491346">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mehta</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Goichowski</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Treatment of heparin induced thrombocytopenia and thrombosis during the first tri-mester of pregnancy</article-title>. <source>J Thromb Haemost</source>. <year>2004</year>;<volume>2</volume>(<issue>9</issue>):<fpage>1665</fpage>–<lpage>1666</lpage>.</citation>
</ref>
<ref id="bibr13-1076029613491346">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scott</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Gernsheimer</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Honari</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gibbons</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gibran</surname>
<given-names>NS</given-names>
</name>
</person-group>. <article-title>Arterial and venous complications of heparin-induced thrombocytopenia in burn patients</article-title>. <source>J Burn Care Res</source>. <year>2007</year>;<volume>28</volume>(<issue>1</issue>):<fpage>71</fpage>–<lpage>75</lpage>.</citation>
</ref>
<ref id="bibr14-1076029613491346">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thompson</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Lawrence</surname>
<given-names>VA</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>GE</given-names>
</name>
</person-group>. <article-title>HIV infection increases the risk of heparin-induced thrombocytopenia</article-title>. <source>Clin Inf Dis</source>. <year>2007</year>;<volume>45</volume>(<issue>10</issue>):<fpage>1393</fpage>–<lpage>1396</lpage>.</citation>
</ref>
<ref id="bibr15-1076029613491346">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawano</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Toyoda</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Miyata</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Heparin-induced thrombocytopenia: a serious complication of heparin therapy for acute stroke</article-title>. <source>Cerebrovasc Dis</source>. <year>2008</year>;<volume>26</volume>(<issue>6</issue>):<fpage>641</fpage>–<lpage>649</lpage>.</citation>
</ref>
<ref id="bibr16-1076029613491346">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warkentin</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Kelton</surname>
<given-names>JG</given-names>
</name>
</person-group>. <article-title>A 14-year study of heparin-induced thrombocytopenia</article-title>. <source>Am J Med</source>. <year>1996</year>;<volume>101</volume>(<issue>5</issue>):<fpage>502</fpage>–<lpage>507</lpage>.</citation>
</ref>
<ref id="bibr17-1076029613491346">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wallis</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Workman</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>BF</given-names>
</name>
<name>
<surname>Pifarre</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Moran</surname>
<given-names>JF</given-names>
</name>
</person-group>. <article-title>Failure of early heparin cessation as a treatment for heparin-induced thrombocytopenia</article-title>. <source>Am J Med</source>. <year>1999</year>;<volume>106</volume>(<issue>6</issue>):<fpage>629</fpage>–<lpage>635</lpage>.</citation>
</ref>
<ref id="bibr18-1076029613491346">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elalamy</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Tardy-Poncet</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Mulot</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Risk factors for unfavorable clinical outcome in patients with documented heparin-induced thrombocytopenia</article-title>. <source>Thromb Res</source>. <year>2009</year>;<volume>124</volume>(<issue>5</issue>):<fpage>554</fpage>–<lpage>559</lpage>.</citation>
</ref>
<ref id="bibr19-1076029613491346">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nand</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Yuen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Yetter</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schmulbach</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gross</surname>
<given-names>Fisher S</given-names>
</name>
</person-group>. <article-title>Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution</article-title>. <source>Am J Hematol</source>. <year>1997</year>;<volume>56</volume>(<issue>1</issue>):<fpage>12</fpage>–<lpage>16</lpage>.</citation>
</ref>
<ref id="bibr20-1076029613491346">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brieger</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Mak</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Kottke-Marchant</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Topol</surname>
<given-names>EJ</given-names>
</name>
</person-group>. <article-title>Heparin-induced thrombocytopenia</article-title>. <source>J Am Coll Cardiol</source>. <year>1998</year>;<volume>31</volume>(<issue>7</issue>):<fpage>1449</fpage>–<lpage>1459</lpage>.</citation>
</ref>
<ref id="bibr21-1076029613491346">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Francis</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Palmer</surname>
<given-names>GJ</given-names>
<suffix>III</suffix>
</name>
<name>
<surname>Moroose</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Drexler</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery</article-title>. <source>Ann Thorac Surg</source>. <year>2003</year>;<volume>75</volume>(<issue>1</issue>):<fpage>17</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr22-1076029613491346">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gruel</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Pouplard</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Biological and clinical features of low-molecular weight heparin-induced thrombocytopenia</article-title>. <source>Br J Haematol</source>. <year>2003</year>;<volume>121</volume>(<issue>5</issue>):<fpage>786</fpage>–<lpage>792</lpage>.</citation>
</ref>
<ref id="bibr23-1076029613491346">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warkentin</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Levine</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Hirsh</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin</article-title>. <source>N Engl J Med</source>. <year>1995</year>;<volume>332</volume>(<issue>20</issue>):<fpage>1330</fpage>–<lpage>1335</lpage>.</citation>
</ref>
<ref id="bibr24-1076029613491346">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levine</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>McCollum</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hurstings</surname>
<given-names>MJ</given-names>
</name>
</person-group>. <article-title>How frequently is venous thromboembolism in heparin-treated patients associated with heparin-induced thrombocytopenia?</article-title> <source>Chest</source>. <year>2006</year>;<volume>130</volume>(<issue>3</issue>):<fpage>681</fpage>–<lpage>687</lpage>.</citation>
</ref>
<ref id="bibr25-1076029613491346">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lindhoff-Last</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Nakov</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Misselwitz</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Breddin</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>Bauersachs</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin</article-title>. <source>Br J Haematol</source>. <year>2002</year>;<volume>118</volume>(<issue>4</issue>):<fpage>1137</fpage>–<lpage>1142</lpage>.</citation>
</ref>
<ref id="bibr26-1076029613491346">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ban-Hoefen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Heparin-induced thrombocytopenia and thrombosis in a tertiary care hospital</article-title>. <source>Thromb Res</source>. <year>2009</year>;<volume>124</volume>(<issue>2</issue>):<fpage>189</fpage>–<lpage>192</lpage>.</citation>
</ref>
<ref id="bibr27-1076029613491346">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walenga</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Prechel</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Jeske</surname>
<given-names>WP</given-names>
</name>
<name>
<surname>Bakhos</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Unfractionated heparin compared with low-molecular-weight heparin as related to heparin-induced thrombocytopenia</article-title>. <source>Curr Opin Pulm Med</source>. <year>2005</year>;<volume>11</volume>(<issue>5</issue>):<fpage>385</fpage>–<lpage>391</lpage>.</citation>
</ref>
<ref id="bibr28-1076029613491346">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stein</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Hull</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Matta</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Yaekoub</surname>
<given-names>AY</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Incidence of thrombocytopenia in hospitalized patients with venous thromboembolism</article-title>. <source>Am J Med</source>. <year>2009</year>;<volume>122</volume>(<issue>10</issue>):<fpage>919</fpage>–<lpage>930</lpage>.</citation>
</ref>
<ref id="bibr29-1076029613491346">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prandoni</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Siragusa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Girolami</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study</article-title>. <source>Blood</source>. <year>2005</year>;<volume>106</volume>(<issue>9</issue>):<fpage>3049</fpage>–<lpage>3054</lpage>.</citation>
</ref>
<ref id="bibr30-1076029613491346">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kadidal</surname>
<given-names>VV</given-names>
</name>
<name>
<surname>Mayo</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Horne</surname>
<given-names>MK</given-names>
</name>
</person-group>. <article-title>Heparin-induced thrombocytopenia (HIT) due to heparin flushes: a report of three cases</article-title>. <source>J Intern Med</source>. <year>1999</year>;<volume>246</volume>(<issue>3</issue>):<fpage>325</fpage>–<lpage>329</lpage>.</citation>
</ref>
<ref id="bibr31-1076029613491346">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Linkins</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Dans</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Moores</surname>
<given-names>LK</given-names>
</name>
<etal/>
</person-group>. <article-title>Treatment and prevention of heparin-induced thrombocytopenia: American college of chest physicians evidence-based clinical practice guidelines (9th edition)</article-title>. <source>Chest</source>. <year>2012</year>;(<issue>suppl 141</issue>):<fpage>e495S</fpage>–<lpage>e530S</lpage>.</citation>
</ref>
<ref id="bibr32-1076029613491346">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keeling</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Davidson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>H</given-names>
</name>
</person-group>; <collab collab-type="author">Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology</collab>. <article-title>The management of heparin-induced thrombocytopenia</article-title>. <source>Br J Haematol</source>. <year>2006</year>;<volume>133</volume>(<issue>3</issue>):<fpage>259</fpage>–<lpage>269</lpage>.</citation>
</ref>
<ref id="bibr33-1076029613491346">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warkentin</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Kelton</surname>
<given-names>JG</given-names>
</name>
</person-group>. <article-title>Temporal aspects of heparin-induced thrombocytopenia</article-title>. <source>N Engl J Med</source>. <year>2001</year>;<volume>344</volume>(<issue>17</issue>):<fpage>1286</fpage>–<lpage>1292</lpage>.</citation>
</ref>
<ref id="bibr34-1076029613491346">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lubenow</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kempf</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Eichner</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Eichler</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Carlsson</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Greinacher</surname>
<given-names>A.</given-names>
</name>
</person-group> <article-title>Heparin-induced thrombocytopenia. Temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin</article-title>. <source>Chest</source>. <year>2002</year>;<volume>122</volume>(<issue>1</issue>):<fpage>37</fpage>–<lpage>42</lpage>.</citation>
</ref>
<ref id="bibr35-1076029613491346">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rice</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Attisha</surname>
<given-names>WK</given-names>
</name>
<name>
<surname>Drexler</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>JL</given-names>
</name>
</person-group>. <article-title>Delayed-onset heparin-induced thrombocytopenia</article-title>. <source>Ann Intern Med</source>. <year>2002</year>;<volume>136</volume>(<issue>3</issue>):<fpage>210</fpage>–<lpage>215</lpage>.</citation>
</ref>
<ref id="bibr36-1076029613491346">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lillo-LeLouet</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Boutouyrie</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Alhenc-Gelas</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass</article-title>. <source>J Thromb Haemost</source>. <year>2004</year>;<volume>2</volume>(<issue>11</issue>):<fpage>1882</fpage>–<lpage>1888</lpage>.</citation>
</ref>
<ref id="bibr37-1076029613491346">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Selleng</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Malowsky</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Strobel</surname>
<given-names>U</given-names>
</name>
<etal/>
</person-group>. <article-title>Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive</article-title>. <source>J Thromb Haemost</source>. <year>2009</year>;<volume>8</volume>(<issue>1</issue>):<fpage>27</fpage>–<lpage>29</lpage>.</citation>
</ref>
<ref id="bibr38-1076029613491346">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pouplard</surname>
<given-names>C</given-names>
</name>
<name>
<surname>May</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Regina</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Marchand</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fusciardi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gruel</surname>
<given-names>Y</given-names>
</name>
</person-group>. <article-title>Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies</article-title>. <source>Br J Haematol</source>. <year>2005</year>;<volume>128</volume>(<issue>6</issue>):<fpage>837</fpage>–<lpage>841</lpage>.</citation>
</ref>
<ref id="bibr39-1076029613491346">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lo</surname>
<given-names>GK</given-names>
</name>
<name>
<surname>Juhl</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Warkentin</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Sigouin</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Eichler</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Greinacher</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings</article-title>. <source>J Thromb Haemost</source>. <year>2006</year>;<volume>4</volume>(<issue>4</issue>):<fpage>759</fpage>–<lpage>765</lpage>.</citation>
</ref>
<ref id="bibr40-1076029613491346">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cuker</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Arepally</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Crowther</surname>
<given-names>MA</given-names>
</name>
<etal/>
</person-group>. <article-title>The HIT expert probability (HEP) score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion</article-title>. <source>J Thromb Haemost</source>. <year>2010</year>;<volume>8</volume>(<issue>12</issue>):<fpage>2642</fpage>–<lpage>2650</lpage>.</citation>
</ref>
<ref id="bibr41-1076029613491346">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Messmore</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>Fabbrini</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bird</surname>
<given-names>ML</given-names>
</name>
<etal/>
</person-group>. <article-title>Simple scoring system for early management of heparin-induced thrombocytopia</article-title>. <source>Clin Appl Thromb Hemost</source>. <year>2011</year>;<volume>17</volume>(<issue>2</issue>):<fpage>197</fpage>–<lpage>201</lpage>.</citation>
</ref>
<ref id="bibr42-1076029613491346">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amiral</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bridey</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Dreyfus</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia</article-title>. <source>Thromb Haemost</source>. <year>1992</year>;<volume>68</volume>(<issue>1</issue>):<fpage>95</fpage>–<lpage>96</lpage>.</citation>
</ref>
<ref id="bibr43-1076029613491346">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greinacher</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Potzsch</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Amiral</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dummel</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Eichner</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mueller-Eckhardt</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Heparin-associated thrombocytopia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen</article-title>. <source>Thromb Haemost</source>. <year>1994</year>;<volume>71</volume>(<issue>2</issue>):<fpage>247</fpage>–<lpage>251</lpage>.</citation>
</ref>
<ref id="bibr44-1076029613491346">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Visentin</surname>
<given-names>GP</given-names>
</name>
<name>
<surname>Ford</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Aster</surname>
<given-names>RH</given-names>
</name>
</person-group>. <article-title>Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells</article-title>. <source>J Clin Invest</source>. <year>1994</year>;<volume>93</volume>(<issue>1</issue>):<fpage>81</fpage>–<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr45-1076029613491346">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horsewood</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Warkentin</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Hayward</surname>
<given-names>CPM</given-names>
</name>
<name>
<surname>Kelton</surname>
<given-names>JG</given-names>
</name>
</person-group>. <article-title>The epitope specificity of heparin-induced thrombocytopenia</article-title>. <source>Br J Haematol</source>. <year>1996</year>;<volume>95</volume>(<issue>1</issue>):<fpage>161</fpage>–<lpage>167</lpage>.</citation>
</ref>
<ref id="bibr46-1076029613491346">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Newman</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Chong</surname>
<given-names>BH</given-names>
</name>
</person-group>. <article-title>Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation</article-title>. <source>Blood</source>. <year>2000</year>;<volume>96</volume>(<issue>1</issue>):<fpage>182</fpage>–<lpage>187</lpage>.</citation>
</ref>
<ref id="bibr47-1076029613491346">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kelton</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Sheridan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Heparin-induced thrombocytopenia: laboratory studies</article-title>. <source>Blood</source>. <year>1988</year>;<volume>72</volume>(<issue>3</issue>):<fpage>925</fpage>–<lpage>930</lpage>.</citation>
</ref>
<ref id="bibr48-1076029613491346">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warkentin</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Hayward</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Boshkov</surname>
<given-names>LK</given-names>
</name>
<etal/>
</person-group>. <article-title>Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia</article-title>. <source>Blood</source>. <year>1994</year>;<volume>84</volume>(<issue>11</issue>):<fpage>3691</fpage>–<lpage>3699</lpage>.</citation>
</ref>
<ref id="bibr49-1076029613491346">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amiral</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Boyer-Neumann</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Vissac</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia</article-title>. <source>Br J Haematol</source>. <year>1996</year>;<volume>92</volume>(<issue>4</issue>):<fpage>954</fpage>–<lpage>959</lpage>.</citation>
</ref>
<ref id="bibr50-1076029613491346">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fareed</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Walenga</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Hoppensteadt</surname>
<given-names>DA</given-names>
</name>
<etal/>
</person-group>. <article-title>Selectins in the HIT syndrome: pathophysiologic role and therapeutic modulation</article-title>. <source>Semin Thromb Hemost</source>. <year>1999</year>;(<issue>25 suppl 1</issue>):<fpage>37</fpage>–<lpage>42</lpage>.</citation>
</ref>
<ref id="bibr51-1076029613491346">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pouplard</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Iochmann</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Renard</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia</article-title>. <source>Blood</source>. <year>2001</year>;<volume>97</volume>(<issue>10</issue>):<fpage>3300</fpage>–<lpage>3302</lpage>.</citation>
</ref>
<ref id="bibr52-1076029613491346">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blank</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shoenfeld</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tavor</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells</article-title>. <source>Int Immunol</source>. <year>2002</year>;<volume>14</volume>(<issue>2</issue>):<fpage>121</fpage>–<lpage>129</lpage>.</citation>
</ref>
<ref id="bibr53-1076029613491346">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walenga</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Jeske</surname>
<given-names>WP</given-names>
</name>
<name>
<surname>Prechel</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Bakhos</surname>
<given-names>M.</given-names>
</name>
</person-group> <article-title>Newer insights on the mechanism of heparin-induced thrombocytopenia</article-title>. <source>Sem Thromb Hemost</source>. <year>2004</year>;(<issue>30 suppl 1</issue>):<fpage>57</fpage>–<lpage>67</lpage>.</citation>
</ref>
<ref id="bibr54-1076029613491346">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walenga</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Jeske</surname>
<given-names>WP</given-names>
</name>
<name>
<surname>Messmore</surname>
<given-names>HL.</given-names>
</name>
</person-group> <article-title>Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia</article-title>. <source>J Thromb Thrombolysis</source>. <year>2000</year>;(<issue>10 suppl 1</issue>):<fpage>13</fpage>–<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr55-1076029613491346">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tardy-Poncet</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Piot</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chapelle</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Thrombin generation and heparin-induced thrombocytopenia</article-title>. <source>J Thromb Haemost</source>. <year>2009</year>;<volume>7</volume>(<issue>9</issue>):<fpage>1474</fpage>–<lpage>1481</lpage>.</citation>
</ref>
<ref id="bibr56-1076029613491346">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kelton</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Hurstings</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Heddle</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>BE</given-names>
</name>
</person-group>. <article-title>Predictors of clinical outcome in patients with heparin-induced thrombocytopenia treated with direct thrombin inhibition</article-title>. <source>Blood Coagul Fibrinolysis</source>. <year>2008</year>;<volume>19</volume>(<issue>6</issue>):<fpage>471</fpage>–<lpage>475</lpage>.</citation>
</ref>
<ref id="bibr57-1076029613491346">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lubenow</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hinz</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Thomaschewski</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia</article-title>. <source>Blood</source>. <year>2010</year>;<volume>115</volume>:<fpage>1797</fpage>–<lpage>1803</lpage>.</citation>
</ref>
<ref id="bibr58-1076029613491346">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Assman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Boeken</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Feindt</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Schurr</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Akhyari</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lichtenberg</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Heparin-induced thrombocytopenia type II after cardiac surgery: predictors and outcome</article-title>. <source>Thorac Cardiovasc Surg</source>. <year>2010</year>;<volume>58</volume>(<issue>8</issue>):<fpage>463</fpage>–<lpage>467</lpage>.</citation>
</ref>
<ref id="bibr59-1076029613491346">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warkentin</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Marder</surname>
<given-names>VJ</given-names>
</name>
<name>
<surname>Greinacher</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization</article-title>. <source>J Thromb Haemost</source>. <year>2010</year>;<volume>8</volume>(<issue>3</issue>):<fpage>504</fpage>–<lpage>512</lpage>.</citation>
</ref>
<ref id="bibr60-1076029613491346">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stribling</surname>
<given-names>WK</given-names>
</name>
<name>
<surname>Slaughter</surname>
<given-names>TF</given-names>
</name>
<name>
<surname>Houle</surname>
<given-names>TT</given-names>
</name>
<name>
<surname>Sane</surname>
<given-names>DC</given-names>
</name>
</person-group>. <article-title>Beyond the platelet count: heparin antibodies as independent risk predictors</article-title>. <source>Am Heart J</source>. <year>2007</year>;<volume>153</volume>(<issue>6</issue>):<fpage>900</fpage>–<lpage>906</lpage>.</citation>
</ref>
<ref id="bibr61-1076029613491346">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheridan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kelton</surname>
<given-names>JG</given-names>
</name>
</person-group>. <article-title>A diagnostic test for heparin-induced thrombocytopenia</article-title>. <source>Blood</source>. <year>1986</year>;<volume>67</volume>(<issue>1</issue>):<fpage>27</fpage>–<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr62-1076029613491346">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greinacher</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Michels</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Kiefel</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Mueller-Eckhardt</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>A rapid and sensitive test for diagnosing heparin-induced thrombocytopenia</article-title>. <source>Thromb Haemost</source>. <year>1991</year>;<volume>66</volume>(<issue>6</issue>):<fpage>734</fpage>–<lpage>736</lpage>.</citation>
</ref>
<ref id="bibr63-1076029613491346">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chong</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Burgess</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ismail</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia</article-title>. <source>Thromb Haemost</source>. <year>1993</year>;<volume>69</volume>(<issue>4</issue>):<fpage>344</fpage>–<lpage>350</lpage>.</citation>
</ref>
<ref id="bibr64-1076029613491346">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prechel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jeske</surname>
<given-names>WP</given-names>
</name>
<name>
<surname>Walenga</surname>
<given-names>JM</given-names>
</name>
</person-group>. <article-title>Laboratory methods and management of patients with heparin-induced thrombocytopenia</article-title>. <source>Methods Mol Biol</source>. <year>2010</year>;<volume>663</volume>:<fpage>133</fpage>–<lpage>156</lpage>.</citation>
</ref>
<ref id="bibr65-1076029613491346">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walenga</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Jeske</surname>
<given-names>WP</given-names>
</name>
<name>
<surname>Fasanella</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Ahmad</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bakhos</surname>
<given-names>M.</given-names>
</name>
</person-group> <article-title>Laboratory diagnosis of heparin-induced thrombocytopenia</article-title>. <source>Clin Appl Thromb Hemost</source>. <year>1999</year>;(<issue>5 suppl 1</issue>):<fpage>S21</fpage>–<lpage>S27</lpage>.</citation>
</ref>
<ref id="bibr66-1076029613491346">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greinacher</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Amiral</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dummel</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Vissac</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kiefel</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Mueller-Eckhardt</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor4/heparin enzyme-linked immunosorbent assay</article-title>. <source>Transfusion</source>. <year>1994</year>;<volume>34</volume>(<issue>5</issue>):<fpage>381</fpage>–<lpage>385</lpage>.</citation>
</ref>
<ref id="bibr67-1076029613491346">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walenga</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Jeske</surname>
<given-names>WP</given-names>
</name>
<name>
<surname>Fasanella</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Bakhos</surname>
<given-names>M.</given-names>
</name>
</person-group> <article-title>Laboratory tests for the diagnosis of heparin-induced thrombocytopenia</article-title>. <source>Semin Thromb Hemost</source>. <year>1999</year>;(<issue>25 suppl 1</issue>):<fpage>43</fpage>–<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr68-1076029613491346">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pouplard</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Amiral</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Borg</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Laporte-Simitsidis</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Delahousse</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gruel</surname>
<given-names>Y</given-names>
</name>
</person-group>. <article-title>Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia</article-title>. <source>Am J Clin Pathol</source>. <year>1999</year>;<volume>111</volume>(<issue>5</issue>):<fpage>700</fpage>–<lpage>706</lpage>.</citation>
</ref>
<ref id="bibr69-1076029613491346">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lindhoff-Last</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Eichler</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>A prospective study on the incidence and clinical relevance of heparin-induced antibodies in patients after vascular surgery</article-title>. <source>Thromb Res</source>. <year>2000</year>;<volume>97</volume>(<issue>6</issue>):<fpage>387</fpage>–<lpage>393</lpage>.</citation>
</ref>
<ref id="bibr70-1076029613491346">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmad</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Haas</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hoppensteadt</surname>
<given-names>DA</given-names>
</name>
</person-group>. <article-title>Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies</article-title>. <source>Thromb Res</source>. <year>2002</year>;<volume>108</volume>(<issue>1</issue>):<fpage>49</fpage>–<lpage>55</lpage>.</citation>
</ref>
<ref id="bibr71-1076029613491346">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levine</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Hergenroeder</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Hurstings</surname>
<given-names>MJ</given-names>
</name>
</person-group>. <article-title>Heparin-platelet factor 4 antibodies in intensive care patients: an observational seroprevalence study</article-title>. <source>J Thromb Thrombolysis</source>. <year>2010</year>;<volume>30</volume>(<issue>2</issue>):<fpage>142</fpage>–<lpage>148</lpage>.</citation>
</ref>
<ref id="bibr72-1076029613491346">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zwicker</surname>
<given-names>JI</given-names>
</name>
<name>
<surname>Uhl</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>WY</given-names>
</name>
<name>
<surname>Shaz</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>KA</given-names>
</name>
</person-group>. <article-title>Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia</article-title>. <source>J Thromb Haemost</source>. <year>2004</year>;<volume>2</volume>(<issue>12</issue>):<fpage>2133</fpage>–<lpage>2137</lpage>.</citation>
</ref>
<ref id="bibr73-1076029613491346">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Whitlatch</surname>
<given-names>NL</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Ortel</surname>
<given-names>TL</given-names>
</name>
</person-group>. <article-title>Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia</article-title>. <source>Thromb Haemost</source>. <year>2008</year>;<volume>100</volume>(<issue>4</issue>):<fpage>678</fpage>–<lpage>684</lpage>.</citation>
</ref>
<ref id="bibr74-1076029613491346">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Whitlatch</surname>
<given-names>NL</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Metjian</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Arepally</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Ortel</surname>
<given-names>TL</given-names>
</name>
</person-group>. <article-title>Validation of the high confirmatory step for the diagnosis of heparin-induced thrombocytopenia</article-title>. <source>Blood</source>. <year>2010</year>;<volume>116</volume>(<issue>10</issue>):<fpage>1761</fpage>–<lpage>1766</lpage>.</citation>
</ref>
<ref id="bibr75-1076029613491346">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warkentin</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Sheppard</surname>
<given-names>JI</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Sigouin</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Kelton</surname>
<given-names>JG</given-names>
</name>
</person-group>. <article-title>Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays</article-title>. <source>J Thromb Haemost</source>. <year>2008</year>;<volume>6</volume>(<issue>8</issue>):<fpage>1304</fpage>–<lpage>1312</lpage>.</citation>
</ref>
<ref id="bibr76-1076029613491346">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lewis</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Wallis</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Leya</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hurstings</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Kelton</surname>
<given-names>JG</given-names>
</name>
</person-group>. <article-title>Argatroban anticoagulation in patients with heparin-induced thrombocytopenia</article-title>. <source>Arch Intern Med</source>. <year>2003</year>;<volume>163</volume>(<issue>15</issue>):<fpage>1849</fpage>–<lpage>1856</lpage>.</citation>
</ref>
<ref id="bibr77-1076029613491346">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lewis</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Wallis</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Berkowitz</surname>
<given-names>SD</given-names>
</name>
</person-group>. <article-title>Argatroban anticoagulation in patients with heparin-induced thrombocytopenia</article-title>. <source>Circulation</source>. <year>2001</year>;<volume>103</volume>(<issue>14</issue>):<fpage>1838</fpage>–<lpage>1843</lpage>.</citation>
</ref>
<ref id="bibr78-1076029613491346">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lewis</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Wallis</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Hurstings</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Levine</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Leya</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Effects of argatoban therapy, demographic variables, and platelet count on thrombotic risk in heparin-induced thrombocytopenia</article-title>. <source>Chest</source>. <year>2006</year>;<volume>129</volume>(<issue>6</issue>):<fpage>1407</fpage>–<lpage>1416</lpage>.</citation>
</ref>
<ref id="bibr79-1076029613491346">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madabushi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cox</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Hossain</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Pharmacokinetic and pharmacodynamic basis for effective argatroban dosing in pediatrics</article-title>. <source>J Clin Pharmacol</source>. <year>2011</year>;<volume>51</volume>(<issue>1</issue>):<fpage>19</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr80-1076029613491346">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gray</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wallis</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Hurstings</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Katz</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>BE</given-names>
</name>
</person-group>. <article-title>Argatroban therapy for heparin-induced thrombocytopenia in acutely ill patients</article-title>. <source>Clin Appl Thromb Hemost</source>. <year>2007</year>;<volume>13</volume>(<issue>4</issue>):<fpage>353</fpage>–<lpage>361</lpage>.</citation>
</ref>
<ref id="bibr81-1076029613491346">
<label>81</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matthai</surname>
<given-names>WH</given-names>
</name>
<name>
<surname>Hursting</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Kelton</surname>
<given-names>JG</given-names>
</name>
</person-group>. <article-title>Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia</article-title>. <source>Thromb Res</source>. <year>2005</year>;<volume>116</volume>(<issue>2</issue>):<fpage>121</fpage>–<lpage>126</lpage>.</citation>
</ref>
<ref id="bibr82-1076029613491346">
<label>82</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hursting</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>PT</given-names>
</name>
</person-group>. <article-title>Argatroban anticoagulation in renal dysfunction: a literature analysis</article-title>. <source>Nephron Clin Pract</source>. <year>2008</year>;<volume>109</volume>(<issue>2</issue>):<fpage>80</fpage>–<lpage>94</lpage>.</citation>
</ref>
<ref id="bibr83-1076029613491346">
<label>83</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greinacher</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Janssens</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Berg</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia</article-title>. <source>Circulation</source>. <year>1999</year>;<volume>100</volume>(<issue>6</issue>):<fpage>587</fpage>–<lpage>593</lpage>.</citation>
</ref>
<ref id="bibr84-1076029613491346">
<label>84</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greinacher</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Volpel</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Janssens</surname>
<given-names>U</given-names>
</name>
</person-group>. <article-title>Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia; a prospective study</article-title>. <source>Circulation</source>. <year>1999</year>;<volume>99</volume>:<fpage>73</fpage>–<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr85-1076029613491346">
<label>85</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greinacher</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lubenow</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Eichler</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia</article-title>. <source>Circulation</source>. <year>2003</year>;<volume>108</volume>(<issue>17</issue>):<fpage>2062</fpage>–<lpage>2065</lpage>.</citation>
</ref>
<ref id="bibr86-1076029613491346">
<label>86</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eichler</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Friesen</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Lubenow</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Jaeger</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Greinacher</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on a aPTT, and clinical relevance</article-title>. <source>Blood</source>. <year>2000</year>;<volume>96</volume>(<issue>7</issue>):<fpage>2373</fpage>–<lpage>2378</lpage>.</citation>
</ref>
<ref id="bibr87-1076029613491346">
<label>87</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levine</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Hursting</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>McCollum</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction</article-title>. <source>Chest</source>. <year>2006</year>;<volume>129</volume>(<issue>5</issue>):<fpage>1167</fpage>–<lpage>1175</lpage>.</citation>
</ref>
<ref id="bibr88-1076029613491346">
<label> 88</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hursting</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Soffer</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia</article-title>. <source>Drug Saf</source>. <year>2009</year>;<volume>32</volume>(<issue>3</issue>):<fpage>203</fpage>–<lpage>218</lpage>.</citation>
</ref>
<ref id="bibr89-1076029613491346">
<label> 89</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lubenow</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Eichler</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lietz</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Greinacher</surname>
<given-names>A.</given-names>
</name>
</person-group> <article-title>Lepirudin in patients with heparin-induced thrombocytopenia—results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2 and HAT-3</article-title>. <source>J Thromb Haemost</source>. <year>2005</year>;<volume>3</volume>(<issue>11</issue>):<fpage>2428</fpage>–<lpage>2436</lpage>.</citation>
</ref>
<ref id="bibr90-1076029613491346">
<label> 90</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tardy</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lecompte</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Boelhen</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin</article-title>. <source>Blood</source>. <year>2006</year>;<volume>108</volume>(<issue>5</issue>):<fpage>1492</fpage>–<lpage>1496</lpage>.</citation>
</ref>
<ref id="bibr91-1076029613491346">
<label> 91</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tschudi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lammle</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Alberio</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients</article-title>. <source>Blood</source>. <year>2009</year>;<volume>113</volume>(<issue>11</issue>):<fpage>2402</fpage>–<lpage>2409</lpage>.</citation>
</ref>
<ref id="bibr92-1076029613491346">
<label> 92</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boyce</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Bandyk</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Bartholomew</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Frame</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Rice</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT study</article-title>. <source>Am J Ther</source>. <year>2011</year>;<volume>18</volume>(<issue>1</issue>):<fpage>14</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr93-1076029613491346">
<label> 93</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levy</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Walenga</surname>
<given-names>JM</given-names>
</name>
</person-group>. <article-title>Desirudin: a summary of recent data in patients with or without risk for heparin-induced thrombocytopenia</article-title>. <source>Chest Phys</source>. <year>2011</year>;<volume>6</volume>(<issue>suppl</issue>):<fpage>3</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr94-1076029613491346">
<label> 94</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kiser</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Burch</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Klem</surname>
<given-names>PM</given-names>
</name>
</person-group>. <article-title>Safety, efficacy and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia</article-title>. <source>Pharmacotherapy</source>. <year>2008</year>;<volume>28</volume>(<issue>9</issue>):<fpage>1115</fpage>–<lpage>1124</lpage>.</citation>
</ref>
<ref id="bibr95-1076029613491346">
<label> 95</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koster</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dyke</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Aldea</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Bivalrudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial</article-title>. <source>Ann Thorac Surg</source>. <year>2007</year>;<volume>83</volume>(<issue>2</issue>):<fpage>572</fpage>–<lpage>577</lpage>.</citation>
</ref>
<ref id="bibr96-1076029613491346">
<label> 96</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dyke</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Aldea</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Koster</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Off-pump coronary bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies</article-title>. <source>Ann Thorac Surg</source>. <year>2007</year>;<volume>84</volume>(<issue>3</issue>):<fpage>836</fpage>–<lpage>840</lpage>.</citation>
</ref>
<ref id="bibr97-1076029613491346">
<label> 97</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahaffey</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Wildermann</surname>
<given-names>NM</given-names>
</name>
<etal/>
</person-group>. <article-title>The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results</article-title>. <source>J Invasive Cardiol</source>. <year>2003</year>;<volume>15</volume>(<issue>111</issue>):<fpage>611</fpage>–<lpage>616</lpage>.</citation>
</ref>
<ref id="bibr98-1076029613491346">
<label> 98</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Comparison of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing an invasive strategy: a meta-analysis of randomized clinical trials</article-title>. <source>Int J Cardiol</source>. <year>2010</year>;<volume>152</volume>(<issue>3</issue>):<fpage>369</fpage>–<lpage>374</lpage>.</citation>
</ref>
<ref id="bibr99-1076029613491346">
<label> 99</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Magnani</surname>
<given-names>HN</given-names>
</name>
<name>
<surname>Gallus</surname>
<given-names>A.</given-names>
</name>
</person-group> <article-title>Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004</article-title>. <source>Thromb Haemost</source>. <year>2006</year>;<volume>95</volume>(<issue>6</issue>):<fpage>967</fpage>–<lpage>981</lpage>.</citation>
</ref>
<ref id="bibr100-1076029613491346">
<label>100</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chong</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Gallus</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Cade</surname>
<given-names>JF</given-names>
</name>
</person-group>. <article-title>Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis: a clinical outcome study</article-title>. <source>Thromb Haemost</source>. <year>2001</year>;<volume>86</volume>(<issue>5</issue>):<fpage>1170</fpage>–<lpage>1175</lpage>.</citation>
</ref>
<ref id="bibr101-1076029613491346">
<label>101</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lindhoff-Last</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kreutzenbeck</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Magnani</surname>
<given-names>HN</given-names>
</name>
</person-group>. <article-title>Treatment of 51 pregnancies with danaparoid because of heparin intolerance</article-title>. <source>Thromb Haemost</source>. <year>2005</year>;<volume>93</volume>(<issue>1</issue>):<fpage>63</fpage>–<lpage>69</lpage>.</citation>
</ref>
<ref id="bibr102-1076029613491346">
<label>102</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tardy</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Tardy-Poncet</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Viallon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Piot</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mazet</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Fatal danaparoid-sodium induced thrombocytopenia and arterial thrombosis</article-title>. <source>Thromb Haemost</source>. <year>1998</year>;<volume>80</volume>(<issue>3</issue>):<fpage>530</fpage>.</citation>
</ref>
<ref id="bibr103-1076029613491346">
<label>103</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farner</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Eichler</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kroll</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Greinacher</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia</article-title>. <source>Thromb Haemost</source>. <year>2001</year>;<volume>85</volume>(<issue>6</issue>):<fpage>950</fpage>–<lpage>957</lpage>.</citation>
</ref>
<ref id="bibr104-1076029613491346">
<label>104</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kodityal</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Manhas</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Udden</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rice</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures</article-title>. <source>Eur J Haematol</source>. <year>2001</year>;<volume>71</volume>:<fpage>109</fpage>–<lpage>113</lpage>.</citation>
</ref>
<ref id="bibr105-1076029613491346">
<label>105</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haas</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Walenga</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Jeske</surname>
<given-names>WP</given-names>
</name>
<name>
<surname>Fareed</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Heparin-induced thrombocytopenia: clinical considerations of alternative anticoagulation with various glycosaminoglycans and thrombin inhibitors</article-title>. <source>Clin Appl Thromb Hemost</source>. <year>1999</year>;<volume>5</volume>(<issue>1</issue>):<fpage>52</fpage>–<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr106-1076029613491346">
<label>106</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lobo</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Finch</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Howard</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Minhas</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia</article-title>. <source>Thromb Haemost</source>. <year>2008</year>;<volume>99</volume>(<issue>1</issue>):<fpage>208</fpage>–<lpage>214</lpage>.</citation>
</ref>
<ref id="bibr107-1076029613491346">
<label>107</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grouzi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kyriakou</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Panagou</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Spiliotopoulou</surname>
<given-names>I</given-names>
</name>
</person-group>. <article-title>Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience</article-title>. <source>Clin Appl Thromb Hemost</source>. <year>2010</year>;<volume>16</volume>(<issue>6</issue>):<fpage>663</fpage>–<lpage>667</lpage>.</citation>
</ref>
<ref id="bibr108-1076029613491346">
<label>108</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warkentin</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Pai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sheppard</surname>
<given-names>JI</given-names>
</name>
<name>
<surname>Schulman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Spyropoulos</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Eikelboom</surname>
<given-names>JW</given-names>
</name>
</person-group>. <article-title>Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series</article-title>. <source>J Thromb Haemost</source>. <year>2011</year>;<volume>9</volume>(<issue>12</issue>):<fpage>2389</fpage>–<lpage>2396</lpage>.</citation>
</ref>
<ref id="bibr109-1076029613491346">
<label>109</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hook</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Abrams</surname>
<given-names>CS</given-names>
</name>
</person-group>. <article-title>Treatment options in heparin-induced thrombocytopenia</article-title>. <source>Curr Opin Hematol</source>. <year>2010</year>;<volume>17</volume>(<issue>5</issue>):<fpage>424</fpage>–<lpage>431</lpage>.</citation>
</ref>
<ref id="bibr110-1076029613491346">
<label>110</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greinacher</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Alban</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Drummel</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Franz</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Mueller-Eckhardt</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Characterization of the structural requirements for a carbohydrate-based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia</article-title>. <source>Thromb Haemost</source>. <year>1995</year>;<volume>74</volume>(<issue>4</issue>):<fpage>886</fpage>–<lpage>892</lpage>.</citation>
</ref>
<ref id="bibr111-1076029613491346">
<label>111</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walenga</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Koza</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Pifarre</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents</article-title>. <source>Clin Appl Thromb Hemost</source>. <year>1996</year>;<volume>2</volume>(<issue>suppl 1</issue>):<fpage>S21</fpage>–<lpage>S27</lpage>.</citation>
</ref>
<ref id="bibr112-1076029613491346">
<label>112</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warkentin</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Elavathil</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Hayward</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Johnston</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Russett</surname>
<given-names>JI</given-names>
</name>
<name>
<surname>Kelton</surname>
<given-names>JG</given-names>
</name>
</person-group>. <article-title>The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia</article-title>. <source>Ann Intern Med</source>. <year>1997</year>;<volume>127</volume>(<issue>9</issue>):<fpage>804</fpage>–<lpage>812</lpage>.</citation>
</ref>
<ref id="bibr113-1076029613491346">
<label>113</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Srinivasan</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Rice</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bartholomew</surname>
<given-names>JR</given-names>
</name>
<etal/>
</person-group>. <article-title>Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia</article-title>. <source>Arch Intern Med</source>. <year>2004</year>;<volume>164</volume>(<issue>1</issue>):<fpage>66</fpage>–<lpage>70</lpage>.</citation>
</ref>
<ref id="bibr114-1076029613491346">
<label>114</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hursting</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>MacFarlane</surname>
<given-names>DE</given-names>
</name>
</person-group>. <article-title>Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia</article-title>. <source>Clin Appl Thromb Hemost</source>. <year>2005</year>;<volume>11</volume>(<issue>3</issue>):<fpage>279</fpage>–<lpage>287</lpage>.</citation>
</ref>
<ref id="bibr115-1076029613491346">
<label>115</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bartholomew</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Hursting</surname>
<given-names>MJ</given-names>
</name>
</person-group>. <article-title>Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR)</article-title>. <source>J Thromb Thrombolysis</source>. <year>2005</year>;<volume>19</volume>(<issue>3</issue>):<fpage>183</fpage>–<lpage>188</lpage>.</citation>
</ref>
<ref id="bibr116-1076029613491346">
<label>116</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walenga</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Drenth</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Mayuga</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effect on coagulation factor testing</article-title>. <source>Clin Appl Thromb Hemost</source>. <year>2008</year>;<volume>14</volume>(<issue>3</issue>):<fpage>325</fpage>–<lpage>331</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>